
Therapeutic Area | MeSH |
|---|---|
| nutritional and metabolic diseases | D009750 |
| endocrine system diseases | D004700 |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| INVOKAMET XR | Johnson & Johnson | N-205879 RX | 2016-09-20 | 4 products, RLD, RS |
| INVOKAMET | Johnson & Johnson | N-204353 RX | 2014-08-08 | 4 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| JANUMET XR | Merck & Co | N-202270 RX | 2012-02-02 | 3 products, RLD, RS |
| JANUMET | Merck & Co | N-022044 RX | 2007-03-30 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| JENTADUETO XR | Boehringer Ingelheim | N-208026 RX | 2016-05-27 | 2 products, RLD, RS |
| JENTADUETO | Boehringer Ingelheim | N-201281 RX | 2012-01-30 | 3 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| KOMBIGLYZE XR | AstraZeneca | N-200678 DISCN | 2010-11-05 | 3 products, RLD |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| QTERNMET XR | AstraZeneca | N-210874 DISCN | 2019-05-02 | 4 products, RLD |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SYNJARDY XR | Boehringer Ingelheim | N-208658 RX | 2016-12-09 | 4 products, RLD, RS |
| SYNJARDY | Boehringer Ingelheim | N-206111 RX | 2015-08-26 | 4 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| TRIJARDY XR | Boehringer Ingelheim | N-212614 RX | 2020-01-27 | 4 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| XIGDUO XR | AstraZeneca | N-205649 RX | 2014-10-29 | 5 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ZITUVIMET XR | Zydus Therapeutics | N-216778 RX | 2024-07-18 | 3 products, RLD, RS |
| ZITUVIMET | Zydus Therapeutics | N-216743 RX | 2023-11-03 | 2 products, RLD, RS |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| AVANDAMET | SB Pharmco | N-021410 DISCN | 2002-10-10 | 5 products, RLD |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| GLUCOVANCE | Bristol Myers Squibb | N-021178 DISCN | 2000-07-31 | 3 products, RLD |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| METAGLIP | Bristol Myers Squibb | N-021460 DISCN | 2002-10-21 | 3 products, RLD |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PRANDIMET | Novo Nordisk | N-022386 DISCN | 2008-06-23 | 2 products, RLD |
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| SEGLUROMET | Merck & Co | N-209806 RX | 2017-12-19 | 4 products, RLD, RS |
Brand Name | Status | Last Update |
|---|---|---|
| actoplus met | New Drug Application | 2025-03-27 |
| alogliptin and metformin hydrochloride | NDA authorized generic | 2025-04-11 |
| appformin | unapproved drug other | 2011-08-08 |
| appformin-d | unapproved drug other | 2011-08-08 |
| avandamet | New Drug Application | 2012-08-30 |
| dapagliflozin and metformin hydrochloride | NDA authorized generic | 2024-12-20 |
| fortamet | New Drug Application | 2010-03-15 |
| glipizide and metformin hydrochloride | ANDA | 2018-12-11 |
| glipizide and metformin hydrochloride glipizide and metformin hydrochloride | ANDA | 2024-12-04 |
| glipizide and metformin hcl | ANDA | 2025-05-22 |
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| type 2 diabetes mellitus | EFO_0001360 | D003924 | E11 |
Expiration | Code | ||
|---|---|---|---|
EMPAGLIFLOZIN / METFORMIN HYDROCHLORIDE, SYNJARDY, BOEHRINGER INGELHEIM | |||
| 2026-12-20 | PED | ||
| 2026-06-20 | NPP | ||
EMPAGLIFLOZIN / METFORMIN HYDROCHLORIDE, SYNJARDY XR, BOEHRINGER INGELHEIM | |||
| 2026-12-20 | PED | ||
| 2026-06-20 | M-296 | ||
LINAGLIPTIN / METFORMIN HYDROCHLORIDE, JENTADUETO, BOEHRINGER INGELHEIM | |||
| 2026-12-20 | PED | ||
| 2026-06-20 | M-295 | ||
| 2023-03-30 | M-252 | ||
LINAGLIPTIN / METFORMIN HYDROCHLORIDE, JENTADUETO XR, BOEHRINGER INGELHEIM | |||
| 2026-12-20 | PED | ||
| 2026-06-20 | M-295 | ||
| 2023-03-30 | M-252 | ||
ERTUGLIFLOZIN / METFORMIN HYDROCHLORIDE, SEGLUROMET, MSD SUB MERCK | |||
| 2024-09-17 | M-275 | ||
METFORMIN HYDROCHLORIDE / SITAGLIPTIN PHOSPHATE, JANUMET, MSD SUB MERCK | |||
| 2024-06-04 | PED | ||
| 2023-12-04 | M-187 | ||
| 2023-02-12 | PED | ||
METFORMIN HYDROCHLORIDE / SITAGLIPTIN PHOSPHATE, JANUMET XR, MERCK SHARP DOHME | |||
| 2024-06-04 | PED | ||
| 2023-12-04 | M-187 | ||
| 2023-02-12 | PED | ||
Patent | Expires | Flag | FDA Information |
|---|---|---|---|
| Metformin Hydrochloride, Riomet Er, Sun Pharm | |||
| 9962336 | 2035-05-01 | DP | |
| Empagliflozin / Linagliptin / Metformin Hydrochloride, Trijardy Xr, Boehringer Ingelheim | |||
| 9949998 | 2034-06-11 | U-2290, U-2731 | |
| 10258637 | 2034-04-03 | U-2290, U-2731 | |
| 11090323 | 2034-04-03 | U-3192, U-3193 | |
| 10596120 | 2032-03-07 | DP | U-2775, U-2776, U-2790, U-2792 |
| 11564886 | 2032-03-07 | DP | U-3531 |
| 10406172 | 2030-06-15 | DP | U-2733 |
| 9155705 | 2030-05-21 | DP | |
| 8551957 | 2029-10-14 | DP | U-2730 |
| 9415016 | 2029-04-02 | DP | |
| 10022379 | 2029-04-02 | U-2339, U-2732 | |
| 7579449 | 2028-08-01 | DP | |
| 7713938 | 2027-04-15 | DS, DP | |
| 8883805 | 2025-11-26 | DP | |
| 7407955 | 2025-05-02 | DS, DP | |
| 8119648 | 2023-08-12 | U-802, U-1652 | |
| 8178541 | 2023-08-12 | DP | U-775, U-1652, U-1853 |
| Empagliflozin / Metformin Hydrochloride, Synjardy, Boehringer Ingelheim | |||
| 9949997 | 2034-05-17 | U-3532, U-3533 | |
| 10610489 | 2030-09-30 | DP | |
| Linagliptin / Metformin Hydrochloride, Jentadueto Xr, Boehringer Ingelheim | |||
| 9555001 | 2033-03-06 | DP | U-1967, U-1968 |
| 9173859 | 2027-05-04 | DP | U-1503 |
| Dapagliflozin / Metformin Hydrochloride, Xigduo Xr, Astrazeneca Ab | |||
| 9616028 | 2030-11-12 | DP | |
| 8685934 | 2030-05-26 | U-1522 | |
| 7919598 | 2029-12-16 | DP | |
| 8501698 | 2027-06-20 | DP | U-493 |
| 6515117 | 2025-10-04 | DS, DP | U-493 |
| Ertugliflozin / Metformin Hydrochloride, Segluromet, Msd Sub Merck | |||
| 9308204 | 2030-10-21 | DP | |
| 9439902 | 2030-10-21 | U-2214 | |
| 8080580 | 2030-07-13 | DS, DP | U-2214 |
| Canagliflozin / Metformin Hydrochloride, Invokamet, Janssen Pharms | |||
| 11576894 | 2030-07-06 | DP | |
| 7943582 | 2029-02-26 | DS, DP | U-493, U-2441, U-2632 |
| 8513202 | 2027-12-03 | DS, DP | U-493, U-2441, U-2632 |
| 7943788 | 2027-07-14 | DS, DP | |
| 8222219 | 2025-04-11 | U-493, U-2441, U-2632 | |
| 8785403 | 2024-07-30 | DP | |
| Linagliptin / Metformin Hydrochloride, Jentadueto, Boehringer Ingelheim | |||
| 8846695 | 2030-06-04 | U-1503 | |
| 10973827 | 2029-04-02 | DP | |
| 8673927 | 2027-05-04 | U-1503 | |
| Alogliptin Benzoate / Metformin Hydrochloride, Kazano, Takeda Pharms Usa | |||
| 8900638 | 2029-05-24 | DP | |
| 7807689 | 2028-06-27 | DS, DP | U-1337 |
| 8288539 | 2025-06-24 | DP | |
| 8173663 | 2025-03-15 | U-1338 | |
| Metformin Hydrochloride / Pioglitazone Hydrochloride, Actoplus Met, Takeda Pharms Usa | |||
| 9320714 | 2029-02-03 | DP | |
| 9101660 | 2027-01-22 | DP | |

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 9 | — | — | — | — | 9 |
| Drug common name | Metformin |
| INN | metformin |
| Description | Metformin is a member of the class of guanidines that is biguanide the carrying two methyl substituents at position 1. It has a role as a hypoglycemic agent, a xenobiotic, an environmental contaminant and a geroprotector. It is functionally related to a biguanide. It is a conjugate base of a metformin(1+). |
| Classification | Small molecule |
| Drug class | hypoglycemics (phenformin type) |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | CN(C)C(=N)NC(=N)N |
| PDB | — |
| CAS-ID | 657-24-9 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1431 |
| ChEBI ID | 6801 |
| PubChem CID | 4091 |
| DrugBank | DB00331 |
| UNII ID | 9100L32L2N (ChemIDplus, GSRS) |


















































